Pancreatic Cancer

The FDA has permitted expanded access to daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma.

Phase 1/2 data from 2 separate studies have shown signals of improved survival and safety with the agent, supporting its evaluation in a phase 3 trial.

Treatment with daraxonrasib led to PFS and OS benefits vs SOC cytotoxic chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.

Shubham Pant, MD, MBBS, discusses recent treatment advancements across gastrointestinal malignancies.

We recap the top regulatory decisions of March in GI malignancies.

Vincent Picozzi, MD, discusses the importance of the FDA approval of Optune Pax for TTField development in locally advanced pancreatic cancer.

Penipulimab plus anlotinib and chemotherapy showed improved efficacy compared with chemotherapy alone in treatment-naïve metastatic pancreatic cancer.

GFH375 produced responses and tumor shrinkage in heavily pretreated pancreatic ductal adenocarcinoma harboring KRAS G12D mutations.

Specific HLA types were not found to be associated with robust mKRAS-specific T-cell responses after treatment with ELI-002 7P in patients with PDAC.

Vopimetostat elicited responses and was considered tolerable in patients with MTAP-deleted solid tumors, including pancreatic and lung cancers.

To extend the benefits of CTLA-4 inhibitors to poorly immunogenic tumors such as HCC and CRC, investigators are developing Fc-enhanced CTLA-4 inhibitors.

Elraglusib plus gemcitabine/nab-paclitaxel displayed an OS benefit vs chemotherapy alone in untreated metastatic pancreatic ductal adenocarcinoma.

TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

The addition of VCN-01 to gemcitabine and nab-paclitaxel improved survival in newly diagnosed metastatic pancreatic cancer.

Study investigators are aiming to leverage therapy resistance, particularly in patients with solid tumors after receiving available RAS inhibitors.

The addition of elraglusib to gemcitabine and nab-paclitaxel improved overall survival is first-line metastatic pancreatic cancer.

Overall survival data were linked with baseline geriatric assessment and QOL scores in patients with metastatic pancreatic ductal adenocarcinoma.

Treatment with daraxonrasib at the phase 3 dose of 300 mg was well tolerated, had favorable dose intensity, and showed efficacy in RAS–mutated PDAC.

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

The median OS with frontline FOLFIRINOX was numerically lower than that seen with frontline NALIRIFOX in patients with metastatic PDAC.

Pamrevlumab plus chemotherapy failed to demonstrate a survival benefit in patients with locally advanced, unresectable pancreatic cancer.

Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12D–mutated PDAC.

First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.

LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.